Michelle Kirschner, Clinical Lead and Medical Advisory Board Chairman at OneVillage, shared a post on LinkedIn:
“I’m gifting you this must-read Wall Street Journal article: “The Hidden Risks of America’s Most Popular Prescription Painkiller.”
Gabapentin has soared in popularity as an opioid alternative—but research shows it isn’t as safe or effective as many believe. Risks include dementia, suicidal behavior, severe breathing problems, edema, and withdrawal symptoms suggesting dependence—even when taken as prescribed.
This is a wake-up call for oncology supportive care. Gabapentin is often prescribed for chemotherapy-induced peripheral neuropathy (CIPN), yet ASCO and NCCN guidelines do NOT recommend it for prevention or treatment. The only drug with evidence for painful CIPN? Duloxetine.
What you’ll learn in the full article:
Why gabapentin is overused and misunderstood
Guideline-based CIPN care: PT first, Duloxetine second
CSPN resources for clinicians and patients
Insights from Dr. Katie Schmitt on why physical therapy should precede pharmacologic treatment
Are PT referrals standard in your practice—or do we still default to meds first?
Share your thoughts and join the conversation.
More posts featuring Michelle Kirschner on OncoDaily.